JPS6322507A - External preparation for skin - Google Patents
External preparation for skinInfo
- Publication number
- JPS6322507A JPS6322507A JP61165401A JP16540186A JPS6322507A JP S6322507 A JPS6322507 A JP S6322507A JP 61165401 A JP61165401 A JP 61165401A JP 16540186 A JP16540186 A JP 16540186A JP S6322507 A JPS6322507 A JP S6322507A
- Authority
- JP
- Japan
- Prior art keywords
- skin
- peony
- external preparation
- preventing
- amount
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 19
- 241000736199 Paeonia Species 0.000 claims abstract description 26
- 235000006484 Paeonia officinalis Nutrition 0.000 claims abstract description 26
- 239000000284 extract Substances 0.000 claims abstract description 20
- 102000011782 Keratins Human genes 0.000 claims abstract description 5
- 108010076876 Keratins Proteins 0.000 claims abstract description 5
- 239000003242 anti bacterial agent Substances 0.000 claims description 11
- 206010000496 acne Diseases 0.000 abstract description 15
- FUWUEFKEXZQKKA-UHFFFAOYSA-N beta-thujaplicin Chemical compound CC(C)C=1C=CC=C(O)C(=O)C=1 FUWUEFKEXZQKKA-UHFFFAOYSA-N 0.000 abstract description 10
- 239000003795 chemical substances by application Substances 0.000 abstract description 10
- 239000000203 mixture Substances 0.000 abstract description 10
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract description 8
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 abstract description 8
- 239000011593 sulfur Substances 0.000 abstract description 8
- 229910052717 sulfur Inorganic materials 0.000 abstract description 8
- -1 KANKOSO 201 Chemical compound 0.000 abstract description 7
- 230000000694 effects Effects 0.000 abstract description 7
- GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 abstract description 7
- 208000001840 Dandruff Diseases 0.000 abstract description 6
- TUFYVOCKVJOUIR-UHFFFAOYSA-N alpha-Thujaplicin Natural products CC(C)C=1C=CC=CC(=O)C=1O TUFYVOCKVJOUIR-UHFFFAOYSA-N 0.000 abstract description 5
- YBHILYKTIRIUTE-UHFFFAOYSA-N berberine Chemical compound C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 YBHILYKTIRIUTE-UHFFFAOYSA-N 0.000 abstract description 5
- 229940093265 berberine Drugs 0.000 abstract description 5
- QISXPYZVZJBNDM-UHFFFAOYSA-N berberine Natural products COc1ccc2C=C3N(Cc2c1OC)C=Cc4cc5OCOc5cc34 QISXPYZVZJBNDM-UHFFFAOYSA-N 0.000 abstract description 5
- 229930007845 β-thujaplicin Natural products 0.000 abstract description 5
- 238000002156 mixing Methods 0.000 abstract description 4
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 abstract description 4
- 229960004889 salicylic acid Drugs 0.000 abstract description 4
- 210000004761 scalp Anatomy 0.000 abstract description 4
- 230000003054 hormonal effect Effects 0.000 abstract description 2
- 230000007794 irritation Effects 0.000 abstract description 2
- 239000000843 powder Substances 0.000 abstract description 2
- 229960001755 resorcinol Drugs 0.000 abstract description 2
- 239000004599 antimicrobial Substances 0.000 abstract 2
- 239000004480 active ingredient Substances 0.000 abstract 1
- 230000000149 penetrating effect Effects 0.000 abstract 1
- 210000003491 skin Anatomy 0.000 description 15
- 208000002874 Acne Vulgaris Diseases 0.000 description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 6
- 239000006071 cream Substances 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 239000003205 fragrance Substances 0.000 description 5
- 239000002674 ointment Substances 0.000 description 5
- 230000028327 secretion Effects 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 239000006210 lotion Substances 0.000 description 3
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 3
- 210000002374 sebum Anatomy 0.000 description 3
- 229940032094 squalane Drugs 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- SLYPOVJCSQHITR-UHFFFAOYSA-N tioxolone Chemical compound OC1=CC=C2SC(=O)OC2=C1 SLYPOVJCSQHITR-UHFFFAOYSA-N 0.000 description 3
- 229960003070 tioxolone Drugs 0.000 description 3
- 230000001256 tonic effect Effects 0.000 description 3
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 235000019438 castor oil Nutrition 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- IYYZUPMFVPLQIF-UHFFFAOYSA-N dibenzothiophene Chemical compound C1=CC=C2C3=CC=CC=C3SC2=C1 IYYZUPMFVPLQIF-UHFFFAOYSA-N 0.000 description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
- 210000004209 hair Anatomy 0.000 description 2
- 210000003780 hair follicle Anatomy 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- BFPYWIDHMRZLRN-UHFFFAOYSA-N 17alpha-ethynyl estradiol Natural products OC1=CC=C2C3CCC(C)(C(CC4)(O)C#C)C4C3CCC2=C1 BFPYWIDHMRZLRN-UHFFFAOYSA-N 0.000 description 1
- IJALWSVNUBBQRA-UHFFFAOYSA-N 4-Isopropyl-3-methylphenol Chemical compound CC(C)C1=CC=C(O)C=C1C IJALWSVNUBBQRA-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 1
- WJLVQTJZDCGNJN-UHFFFAOYSA-N Chlorhexidine hydrochloride Chemical compound Cl.Cl.C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 WJLVQTJZDCGNJN-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 241000186427 Cutibacterium acnes Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 241001106477 Paeoniaceae Species 0.000 description 1
- 206010033733 Papule Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- XEFQLINVKFYRCS-UHFFFAOYSA-N Triclosan Chemical compound OC1=CC(Cl)=CC=C1OC1=CC=C(Cl)C=C1Cl XEFQLINVKFYRCS-UHFFFAOYSA-N 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- 229960001950 benzethonium chloride Drugs 0.000 description 1
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 229910021538 borax Inorganic materials 0.000 description 1
- 229960003260 chlorhexidine Drugs 0.000 description 1
- 229960004504 chlorhexidine hydrochloride Drugs 0.000 description 1
- MXOAEAUPQDYUQM-UHFFFAOYSA-N chlorphenesin Chemical compound OCC(O)COC1=CC=C(Cl)C=C1 MXOAEAUPQDYUQM-UHFFFAOYSA-N 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229960002568 ethinylestradiol Drugs 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 229960004068 hexachlorophene Drugs 0.000 description 1
- ACGUYXCXAPNIKK-UHFFFAOYSA-N hexachlorophene Chemical compound OC1=C(Cl)C=C(Cl)C(Cl)=C1CC1=C(O)C(Cl)=CC(Cl)=C1Cl ACGUYXCXAPNIKK-UHFFFAOYSA-N 0.000 description 1
- 239000012456 homogeneous solution Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- NFIDBGJMFKNGGQ-UHFFFAOYSA-N isopropylmethylphenol Natural products CC(C)CC1=CC=CC=C1O NFIDBGJMFKNGGQ-UHFFFAOYSA-N 0.000 description 1
- 230000003780 keratinization Effects 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 229940055019 propionibacterium acne Drugs 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 210000001732 sebaceous gland Anatomy 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- GCLGEJMYGQKIIW-UHFFFAOYSA-H sodium hexametaphosphate Chemical compound [Na]OP1(=O)OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])O1 GCLGEJMYGQKIIW-UHFFFAOYSA-H 0.000 description 1
- 235000019982 sodium hexametaphosphate Nutrition 0.000 description 1
- 239000004328 sodium tetraborate Substances 0.000 description 1
- 235000010339 sodium tetraborate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000001587 sorbitan monostearate Substances 0.000 description 1
- 235000011076 sorbitan monostearate Nutrition 0.000 description 1
- 229940035048 sorbitan monostearate Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 229960005349 sulfur Drugs 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000001577 tetrasodium phosphonato phosphate Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- ICUTUKXCWQYESQ-UHFFFAOYSA-N triclocarban Chemical compound C1=CC(Cl)=CC=C1NC(=O)NC1=CC=C(Cl)C(Cl)=C1 ICUTUKXCWQYESQ-UHFFFAOYSA-N 0.000 description 1
- 229960001325 triclocarban Drugs 0.000 description 1
- 229960003500 triclosan Drugs 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
- A61Q5/006—Antidandruff preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Medicinal Preparation (AREA)
- Cosmetics (AREA)
Abstract
Description
【発明の詳細な説明】
[産業上の利用分野]
本発明は皮膚外用剤に関する。更に詳しくは、シャクヤ
ク、ボタンピおよびそれらの抽出物からなる群から選ば
れた1種または2種以上と、イオウ、ヒノキチオール、
感光素201号およびチオキソロン等の抗菌剤および/
またはサリチル酸、レゾルシン等の角質剥離剤とを配合
することを特徴とする皮膚外用剤に関するもので、特に
ニキビの予防、治療、処置に有効に働き、また、頭皮に
使用してフケを有効に予防することができる。DETAILED DESCRIPTION OF THE INVENTION [Industrial Field of Application] The present invention relates to an external preparation for skin. More specifically, one or more selected from the group consisting of peonies, botanpi and extracts thereof, sulfur, hinokitiol,
Antibacterial agents such as Photosensor No. 201 and thioxolone and/or
It also relates to external skin preparations that are characterized by containing exfoliating agents such as salicylic acid and resorcinol, and are particularly effective in preventing, treating, and treating acne, and can also be used on the scalp to effectively prevent dandruff. can do.
[従来の技術]
ニキビは主として思春期に発現する皮膚疾患で病名を尋
常性前症といい、臨床的には゛毛嚢脂腺系を中心に上孔
に起こる慢性の炎症性変化゛°と定義されている。[Prior art] Acne is a skin disease that mainly occurs during adolescence and is called pre-vulgaris, which is clinically defined as ``chronic inflammatory changes that occur in the upper foramen, mainly in the pilosebaceous system.'' has been done.
ニキビの病因は現在まだ明らかではなく、種々の要因が
複雑にからみあっている皮膚疾患ではあるが一般には、
皮脂分泌過剰、毛嚢角化、毛嚢内m菌が重要な役割を果
たしていると考えられている。The etiology of acne is still unclear, and although it is a skin disease in which various factors are intricately intertwined, in general,
Excessive sebum secretion, hair follicle keratinization, and microorganisms within the hair follicle are thought to play important roles.
従って、ニキビ治療の外用剤としては、各要因に対応し
て皮脂分泌抑制剤、角質剥離剤および抗菌剤を配合した
クリーム、軟膏が一般に多用されている。しかし、既存
の各種薬剤を配合したニキビ治療剤には種々の欠点があ
った。たとえば、皮脂分泌抑制剤であるエチニルエスト
ラジオールは表皮の生長を抑制し、脂腺の分泌を減少さ
せるものであるが、ホルモン剤がひきおこす副作用は思
春期の男女にとって好ましいものではない。また、イオ
ウ、ヒノキチオール、感光素201号およびベルベリン
等の抗菌剤は、皮膚常在のニキビ菌であるプロピオニバ
クテリウムアクネス(Propionibacteri
um acnes)に対して、試験管内では極めて高い
抗菌力を発揮しても、実際にクリーム、軟膏に配合して
ニキビ治療に用いると期待した治療効果を発揮しないの
がほとんどである。Therefore, as external preparations for treating acne, creams and ointments containing sebum secretion inhibitors, exfoliating agents, and antibacterial agents are commonly used in response to various factors. However, existing acne treatment agents containing various drugs have various drawbacks. For example, ethinyl estradiol, a sebum secretion inhibitor, inhibits epidermal growth and reduces sebaceous gland secretion, but the side effects caused by hormones are not desirable for adolescent boys and girls. In addition, antibacterial agents such as sulfur, hinokitiol, photosensor No. 201, and berberine are effective against Propionibacterium acnes, a acne bacterium resident on the skin.
Even if they exhibit extremely high antibacterial activity against acne (acne) in vitro, in most cases they do not exhibit the expected therapeutic effect when incorporated into creams and ointments and used to treat acne.
[発明が解決しようとする問題点]
本発明者らは、従来の抗菌剤あるいは角質剥離剤の効果
を皮膚上で増大させ、特にニキビの予防、治療、処置に
有効に働き、また、頭皮に使用してフケを有効に予防す
ることができるような化合物を研究していたところ、生
薬であるシャクヤク、ボタンピまたはそれらの抽出物と
、たとえばイオウ、ヒノキチオール、感光素201号お
よびベルベリン等の抗菌剤あるいはサリチル酸、レゾル
シン等の角質剥離剤とを配合することを特撮とする皮膚
外用剤が、この目的を達成できることを見いだして、本
発明を完成した。[Problems to be Solved by the Invention] The present inventors have proposed that the effects of conventional antibacterial agents or exfoliating agents be increased on the skin, and that they are particularly effective in preventing, treating, and treating acne. While researching compounds that can be used to effectively prevent dandruff, we discovered that the herbal medicines peony, botanpi, or their extracts, and antibacterial agents such as sulfur, hinokitiol, photosensor No. 201, and berberine, etc. Alternatively, the present invention was completed based on the discovery that an external skin preparation containing a keratin exfoliant such as salicylic acid or resorcinol can achieve this purpose.
[問題点を解決するための手段]
すなわち本発明は、シャクヤク、ボタンピおよびそれら
の抽出物からなる群から選ばれた1種又は2種以上と、
抗菌剤および/または角質剥離剤とを配合することを特
徴とする皮膚外用剤である。かかる皮膚外用剤は特にニ
キビの予防、治療、処置に有効に働き、また、頭皮に使
用してフケを有効に予防することができる
以下本発明の構成について詳述する。[Means for Solving the Problems] That is, the present invention provides one or more species selected from the group consisting of peonies, botanpi, and extracts thereof;
This external skin preparation is characterized by containing an antibacterial agent and/or a keratin exfoliant. Such external skin preparations are particularly effective in preventing, treating, and treating acne, and can also be used on the scalp to effectively prevent dandruff.The structure of the present invention will be described in detail below.
本発明においては、シャクヤク、ボタンピおよびそれら
の抽出物からなる群から選ばれた任意の1種または2種
以上を用いる。シャクヤクは、ボタン科(Paeon
1aceae)シャクヤクの根、またボタンピは同じく
ボタン科のボタンの根皮を乾燥したものである。シャク
ヤクまたはボタンピの抽出物は上記のシャクヤクの根ま
たはボタンピの根皮を水もしくは水性アルコール、たと
えばエタノールを用い、通常15〜25℃で抽出処理し
て得られる。配合量は末、エキス(抽出溶媒を留去した
残分)ともに全組成中におおむね0.005%(重量%
)以上配合する。配合量の上限は特に限定するものでは
ないが、着色等の商品価値の観点から乾燥残分として合
計で約10%まで配合するのが好ましい。In the present invention, one or more selected from the group consisting of peonies, botanpis, and extracts thereof are used. Peonies are members of the Paeonaceae family.
1aceae) Peony root, also known as peony root, is the dried root bark of peony, which also belongs to the peony family. The extract of Peony or Botanpi is obtained by extracting the roots of the above-mentioned Peony or Botanpi with water or an aqueous alcohol, such as ethanol, usually at 15 to 25°C. The blending amount is approximately 0.005% (wt%) in the entire composition, including the extract (residue after distilling off the extraction solvent).
) or more. The upper limit of the amount to be blended is not particularly limited, but from the viewpoint of commercial value such as coloring, it is preferable to blend up to about 10% in total as a dry residue.
一方、本発明において配合可能な抗菌剤は具体的には以
下のようなものをざす。On the other hand, specific antibacterial agents that can be incorporated in the present invention are as follows.
イオウ・ヒノキチオール・トリクロサン・トリクロロカ
ルバニリド・クロルヘキシジン塩酸塩・クロルヘキシジ
ンクルコンサン塩・へロカルバン・クロロフエネシン・
塩化ベンゼトニウム・塩化ベンザルコニウム・塩化リゾ
チーム・塩酸アルキルジアミノエチルグリシン・イソプ
ロピルメチルフェノール・安息香酸・感光素201号・
ヂモール・ヘキサクロロフェンφベルベリン・チオキソ
ロンおよびそれらの誘導体。Sulfur, hinokitiol, triclosan, trichlorocarbanilide, chlorhexidine hydrochloride, chlorhexidine cluconsanate, helocarban, chlorophenesin,
Benzethonium chloride, benzalkonium chloride, lysozyme chloride, alkyldiaminoethylglycine hydrochloride, isopropylmethylphenol, benzoic acid, photosensitive element No. 201,
Dimol, hexachlorophene, berberine, thioxolone and their derivatives.
配合量としては0.001%以上1o%以下で、好まし
くは0.01%以上5%以下である。The blending amount is 0.001% or more and 10% or less, preferably 0.01% or more and 5% or less.
また本発明において使用可能な角質剥離剤としては具体
的に以下のようなものをきす。Further, as the exfoliating agent that can be used in the present invention, specifically, the following exfoliants are used.
イオウ・サリチル酸・レゾルシン・チオキソロン・ジベ
ンゾチオフェンおよびそれらの誘導体。Sulfur, salicylic acid, resorcinol, thioxolone, dibenzothiophene and their derivatives.
本発明においてはこれらの抗菌剤および角質剥離剤から
なる群から選ばれた任意の1種または2種以上が用いら
れる。In the present invention, any one or more selected from the group consisting of these antibacterial agents and exfoliating agents may be used.
配合量としてはおよそ0.01%以上20%以下である
。The blending amount is approximately 0.01% or more and 20% or less.
本発明の皮膚外用剤には、シャクヤク、ボタンピおよび
それらの抽出物と、抗菌剤あるいは角質剥離剤のほかに
、亜鉛およびその化合物、乳酸等の薬剤や、および剤形
によっても異なるが、油分、界面活性剤、水、エタノー
ル、保湿剤、増粘剤、香料、色素等を本発明の効果を損
なわない範囲で適宜配合することができる。The skin external preparation of the present invention contains peonies, botanpi and their extracts, antibacterial agents or exfoliating agents, as well as drugs such as zinc and its compounds, lactic acid, and although it varies depending on the dosage form, oil, Surfactants, water, ethanol, humectants, thickeners, fragrances, pigments, and the like can be appropriately added within ranges that do not impair the effects of the present invention.
本発明の皮膚外用剤の剤形は、クリーム、軟膏、ローシ
ョン、トニック等外皮に適用できる性状のものであれば
いずれでも良い。The external preparation for skin of the present invention may be in any form as long as it can be applied to the skin, such as cream, ointment, lotion, or tonic.
[発明の効果]
シャクヤク、ボタンピおよびそれらの抽出物の1種また
は2種以上と抗菌剤あるいは角質剥離剤を配合する皮膚
外用剤は非常に良く皮膚に浸透し、刺激やホルモン様副
作用を全く与えず、特にニキビの予防、治療、処置に有
効に働き、また、頭皮に使用してフケを有効に予防する
ことができる。[Effects of the invention] A skin preparation for external use containing one or more of peonies, botanpi and their extracts and an antibacterial agent or exfoliating agent penetrates into the skin very well and causes no irritation or hormonal side effects. In particular, it works effectively in the prevention, treatment, and treatment of acne, and can also be used on the scalp to effectively prevent dandruff.
[実施例コ
実施例1 化粧水
ソルビトール(70%) 3.0gグリセ
リン 5.0gベルベリン
0.02g水
70.8gこれらの成分を混合溶
解し、これに、
アラントイン 0.1gシャクヤ
クエキス 0.5gボタンピ末
0.08gポリオキシエチレン硬化ヒマ
シ油誘導体0、5g
エタノール 20.0g香料
適量の混合溶液を攪拌しな
がら加えて均一な溶液として化粧水を得る。[Example Example 1 Lotion Sorbitol (70%) 3.0g Glycerin 5.0g Berberine
0.02g water
70.8g Mix and dissolve these ingredients, add allantoin 0.1g peony extract 0.5g buttonpi powder
0.08g polyoxyethylene hydrogenated castor oil derivative 0.5g ethanol 20.0g fragrance
Add an appropriate amount of the mixed solution while stirring to obtain a lotion as a homogeneous solution.
実施例2 クリーム
ミツロウ 10.ogパラフィ
ンワックス 6.0gラノリン
3.0gイソプロピルミリステート
6.0gスクワラン
8.0g流動パラフィン 25.0
gシャクヤクエキス 0.1gイオウ
2.Ogポリオキシエチ
レンソルピクンモノヌテアレー)
1. 8gソルビタンモノステアレート 4
.2g防腐剤 適量この成
分を混合し、約75℃で加熱し溶解し、これに約75℃
で加熱した、
プロピレングリコール 2.Ogホウ砂
0.7g水
31.2gの混合液を攪
拌しながら加え、冷却し、55℃で香料を適量加え、4
5℃まで攪拌をつづけ、放置してクリームを得る。Example 2 Cream beeswax 10. og paraffin wax 6.0g lanolin
3.0g isopropyl myristate 6.0g squalane
8.0g liquid paraffin 25.0
g Peony extract 0.1g sulfur 2. Og polyoxyethylene solpicone mononutheary)
1. 8g sorbitan monostearate 4
.. 2g preservative Mix appropriate amount of these ingredients, heat at about 75℃ to dissolve, and add to this at about 75℃
Propylene glycol heated with 2. Og borax
0.7g water
Add 31.2g of the mixture while stirring, cool, add an appropriate amount of fragrance at 55°C,
Continue stirring until 5°C and leave to obtain cream.
実施例3 ヘアトニック
エタノール 55.0g七メッキ
チオール 0.5gニッコールHCO
−60 1.0g香料
適量を室温下、溶解してアルコール相を得た。Example 3 Hair tonic ethanol 55.0g Seven plated thiol 0.5g Nikkor HCO
-60 1.0g fragrance
An appropriate amount was dissolved at room temperature to obtain an alcohol phase.
シャクヤクエキス 0.5g精製水
42.0gグリセリン
1.0g色素
適量の混合液を加熱下に溶解し冷却し水相を得た。Peony extract 0.5g purified water
42.0g glycerin
1.0g dye
An appropriate amount of the mixture was dissolved under heating and cooled to obtain an aqueous phase.
水相に前記アルコール相を加え可溶化してヘアトニック
を得た。The alcohol phase was added to the aqueous phase and solubilized to obtain a hair tonic.
実施例4 軟膏
固体パラフィン 10.0gピースワ
ックス 10.0gスクワラン
10.0gシャクヤクエキス
1.0gイオウ
2.0g香料 適量ワセ
リン 67.0g上記成分を混
合し、混合物を80℃に加熱溶解した後、攪拌冷却を行
い、軟膏を得た。Example 4 Ointment solid paraffin 10.0g peace wax 10.0g squalane
10.0g Peony extract
1.0g sulfur
2.0g fragrance Appropriate amount Vaseline 67.0g The above ingredients were mixed, and the mixture was heated and dissolved at 80°C, and then cooled with stirring to obtain an ointment.
ざらに臨床例を挙げて本発明の効果を詳しく説明する。The effects of the present invention will be explained in detail by briefly giving clinical examples.
(使用薬剤)
下記処方、製造法で得たローションタイプの皮膚外用剤
を使用した。(Medicine used) A lotion-type skin external preparation obtained by the following formulation and manufacturing method was used.
シャクヤクエキス 0.5gP 、
O、E 、 (60モん)硬化ヒマシ油 2.0g
グリセリン 10.ogジプロピレ
ングリコール 10.Ogl、3−ブチレング
リコール 5.0gポリエチレングリコール15
00 5.0g以上を60°Cで加熱溶解する。これ
に感光素201号 0.5gセチル
イソオクタネート 10.0gスクワラン
5.ogメチルパラベン
1.3g!同じ<60’Cに加熱溶解した
ものを添加混合し、ホモミキサーで処理をしてゲルを作
る。Peony extract 0.5gP,
O, E, (60 mon) hydrogenated castor oil 2.0g
Glycerin 10. og dipropylene glycol 10. Ogl, 3-butylene glycol 5.0g polyethylene glycol 15
00 Heat and melt 5.0g or more at 60°C. Add to this Photosensor No. 201 0.5g cetyl isooctanate 10.0g squalane
5. og methylparaben
1.3g! Add and mix the same mixture heated and dissolved at <60'C, and process with a homomixer to make a gel.
次にこのゲルに
カルボキシビニルポリマー 0.3gへキサメ
タリン酸ソーダ 0.08gを、
イオン交換水 11.0gに溶解せ
しめたものを徐添加しホモミキサーで分散した後、
水酸化カリウム 0.12gを
イオン交換水 39.2gに溶解し
たものを添加混合し、ホモミキサーで乳化してローショ
ンタイプの皮膚外用剤を得た。Next, 0.3 g of carboxyvinyl polymer and 0.08 g of sodium hexametaphosphate dissolved in 11.0 g of ion-exchanged water were slowly added to this gel and dispersed with a homomixer, and then 0.12 g of potassium hydroxide was added to the ion-exchanged water. A solution dissolved in 39.2 g of exchanged water was added and mixed, and emulsified with a homomixer to obtain a lotion-type skin preparation for external use.
なお対照薬剤としてシャクヤク抽出物のみまたは感光素
201号のみを配合した外用剤を用い、イオン交換水で
補正した。As a control drug, an external preparation containing only peony extract or only Photosensor No. 201 was used, and correction was made with ion-exchanged water.
症例No、 1〜10 感光素201号のみ配合症例N
o、11〜20シヤクヤク抽出エキスのみ配合
症例No、21〜30 感光素201号十シャクヤク抽
出エキス配合
以上男女計30名に約1カ月使用させな。Case No. 1 to 10 Case N containing only Photosensor No. 201
o, 11-20 Contains only peony extract Case No. 21-30 Photosensor No. 201 10 Contains peony extract or more A total of 30 men and women were allowed to use the product for about 1 month.
(使用方法)
化粧石鹸を用いて顔面をよく洗浄した後、支庁の上にの
み、前記したローションタイプの皮膚外用剤を1日に1
〜3回塗布せしめた。(How to use) After thoroughly washing your face with cosmetic soap, apply the above-mentioned lotion-type skin preparation once a day only on the branch area.
It was applied ~3 times.
(観察項目および観察口)
面飽、丘疹、vA庖の3症状について観察し、その個々
の所見の程度を総合して尋常性前厄の重篤度を、重症、
中等症、軽症の3段階に分けた。経過観察は、治療前、
治療1週間後、2週間後、3週間後、4週間後の各回に
行った。(Observation items and observation points) Observe the three symptoms of vomiting, papules, and vomiting, and synthesize the severity of the individual findings to determine the severity of vulgaris.
The symptoms were divided into three stages: moderate and mild. Follow-up is before treatment,
The test was conducted 1 week, 2 weeks, 3 weeks, and 4 weeks after the treatment.
(全般改善度)
使用前に比較して使用薬剤による症状の改善度、著しく
軽快(1+)) 、かなり軽快(什)、やや軽快(+)
、不変(±)、増悪(−)の5段階に分けた。(Overall improvement level) Compared to before use, the degree of improvement in symptoms due to the drug used, markedly relieved (1+)), considerably relieved (Ti), somewhat relieved (+)
It was divided into 5 stages: no change (±), and worsening (-).
(有用性)
全般改善度から、きわめて有用(1+)) 、かなり有
用(++)、やや有用(+)、無効(±)と判定した。(Usefulness) Based on the overall improvement level, it was judged as extremely useful (1+), quite useful (++), somewhat useful (+), and ineffective (±).
(結果)
男8名、女22名計30名の臨床テスト結果は、感光素
201号のみ配合外用剤使用10名中+(やや有用)が
3名(30χ)、±(無効)が7名(70%)、シャク
ヤク抽出物のみ配合外用剤使用10名中十(やや有用)
が3名(30%)、±(無効)が7名(70χ)、感光
素201号十シャクヤク抽出物配合外用剤使用10名中
+4+(きわめて有用)が3名(30%)、++(かな
り有用)が4名(40%)、+(やや有用)が3名(3
0%)であり、本発明のニキビ治療効果が立証された。(Results) The clinical test results for a total of 30 people, 8 men and 22 women, showed that out of 10 people who used only the external preparation containing Kosensen No. 201, 3 people said + (somewhat useful) (30χ), and 7 people said ± (ineffective). (70%), 10 out of 10 people using external preparations containing only peony extract (slightly useful)
3 people (30%) said ± (ineffective), 7 people (70χ) said that it was +4+ (extremely useful), 3 people (30%) said +4+ (extremely useful), and 3 people (30%) said +4+ (extremely useful). 4 people (40%) said it was useful), and 3 people said it was + (somewhat useful).
0%), demonstrating the effectiveness of the present invention in treating acne.
Claims (1)
から選ばれた1種又は2種以上と、抗菌剤および/また
は角質剥離剤とを配合することを特徴とする皮膚外用剤
。1. A skin preparation for external use, comprising one or more selected from the group consisting of peonies, botanpis, and extracts thereof, and an antibacterial agent and/or a keratin exfoliant.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP61165401A JPS6322507A (en) | 1986-07-14 | 1986-07-14 | External preparation for skin |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP61165401A JPS6322507A (en) | 1986-07-14 | 1986-07-14 | External preparation for skin |
Publications (1)
Publication Number | Publication Date |
---|---|
JPS6322507A true JPS6322507A (en) | 1988-01-30 |
Family
ID=15811706
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP61165401A Pending JPS6322507A (en) | 1986-07-14 | 1986-07-14 | External preparation for skin |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPS6322507A (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994028894A1 (en) * | 1993-06-08 | 1994-12-22 | Fujisawa Pharmaceutical Co., Ltd. | Lotion |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5762212A (en) * | 1980-10-01 | 1982-04-15 | Mitsui Toatsu Chem Inc | Cosmetic |
JPS5823612A (en) * | 1981-08-04 | 1983-02-12 | Osaka Chem Lab | Cosmetic composition containing crude drug component |
JPS58198421A (en) * | 1982-05-14 | 1983-11-18 | Reiko Kosaka | Composition for decoloring skin and treating skin disease |
JPS59137448A (en) * | 1983-01-17 | 1984-08-07 | ヘンケル・コマンデイトゲゼルシヤフト・アウフ・アクテイ−ン | Novel alkoxybenzoic acid ester and fat control cosmetics |
JPS59210010A (en) * | 1983-05-13 | 1984-11-28 | Taisho Pharmaceut Co Ltd | Hair lotion |
JPS60142920A (en) * | 1983-12-01 | 1985-07-29 | ロレアル | Anti-acne agent |
JPS60146829A (en) * | 1984-01-05 | 1985-08-02 | Rooto Seiyaku Kk | Testosterone 5alpha-reductase inhibitor |
-
1986
- 1986-07-14 JP JP61165401A patent/JPS6322507A/en active Pending
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5762212A (en) * | 1980-10-01 | 1982-04-15 | Mitsui Toatsu Chem Inc | Cosmetic |
JPS5823612A (en) * | 1981-08-04 | 1983-02-12 | Osaka Chem Lab | Cosmetic composition containing crude drug component |
JPS58198421A (en) * | 1982-05-14 | 1983-11-18 | Reiko Kosaka | Composition for decoloring skin and treating skin disease |
JPS59137448A (en) * | 1983-01-17 | 1984-08-07 | ヘンケル・コマンデイトゲゼルシヤフト・アウフ・アクテイ−ン | Novel alkoxybenzoic acid ester and fat control cosmetics |
JPS59210010A (en) * | 1983-05-13 | 1984-11-28 | Taisho Pharmaceut Co Ltd | Hair lotion |
JPS60142920A (en) * | 1983-12-01 | 1985-07-29 | ロレアル | Anti-acne agent |
JPS60146829A (en) * | 1984-01-05 | 1985-08-02 | Rooto Seiyaku Kk | Testosterone 5alpha-reductase inhibitor |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994028894A1 (en) * | 1993-06-08 | 1994-12-22 | Fujisawa Pharmaceutical Co., Ltd. | Lotion |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPS60104005A (en) | Skin beutifying cosmetic | |
JP3611128B2 (en) | Testosterone-5-α-reductase inhibitor | |
JPH04124122A (en) | Blackening agent of preventing gray hair | |
JPH0582362B2 (en) | ||
KR100616342B1 (en) | Hair tonic composition | |
JPH03178916A (en) | Skin external agent | |
JPS6360910A (en) | Skin drug for external use | |
JPH11269034A (en) | Skin prepafation for external use for improving acne | |
JPS6322510A (en) | External preparation for skin | |
JP2640101B2 (en) | External preparation for skin | |
JPH11269043A (en) | Cosmetic for scalp and hair | |
JPS63179812A (en) | External preparation for skin | |
JPH04124138A (en) | External preparation for skin | |
JPS6360909A (en) | Skin drug for external use | |
JPS6322506A (en) | External preparation for skin | |
JPS6322507A (en) | External preparation for skin | |
KR20040056079A (en) | Cosmetic composition for preventing and therapeutic for a pimple | |
JPH11302133A (en) | Cosmetic for scalp and hair | |
JPH10265365A (en) | External preparation for skin for pimple | |
JPS6360908A (en) | Skin drug for external use | |
JPH0517202B2 (en) | ||
JPS6360935A (en) | Sebum suppressive agent | |
JPH043363B2 (en) | ||
JPH11116436A (en) | Preparation for external use for skin | |
JPH08231352A (en) | Hair tonic |